2,309 Shares in Stryker Corporation $SYK Acquired by Heartland Bank & Trust Co

Heartland Bank & Trust Co bought a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,309 shares of the medical technology company’s stock, valued at approximately $727,000.

Several other large investors have also recently modified their holdings of SYK. Gables Capital Management Inc. bought a new stake in shares of Stryker in the second quarter worth $25,000. Kilter Group LLC bought a new position in Stryker during the 2nd quarter worth $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the fourth quarter worth about $26,000. Sankala Group LLC acquired a new position in shares of Stryker in the fourth quarter worth approximately $26,000. Finally, United Financial Planning Group LLC acquired a new position in shares of Stryker in the third quarter worth approximately $27,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $329.86 on Friday. The firm has a market cap of $126.52 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.09 and a beta of 0.76. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The business’s 50 day moving average price is $326.99 and its two-hundred day moving average price is $332.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Insider Buying and Selling at Stryker

In other news, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 665,370 shares of company stock valued at $216,238,501. Corporate insiders own 4.60% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Wall Street Analyst Weigh In

SYK has been the subject of a number of recent analyst reports. Citizens Jmp decreased their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research note on Friday, May 1st. UBS Group began coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price for the company. Finally, JPMorgan Chase & Co. dropped their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.